Since FBP1 activity might be suppressed only in some ccRCCs, [18F]-FDG presents a variable uptake in ccRCC lesions; from this biological mechanism, PET/CT with [18F] FDG is not currently recommended in ccRCC management. Here, FBP1 is linked to nonpapillary renal cell carcinoma.